Implementation Process Article 5(3) Nitrosamine
triggered by the EMA Executive Director (ED) requesting the CHMP to conduct a scientific evaluation on the presence of nitrosamine impurities in human medicines containing chemically synthesised active pharmaceutical ingredients (APIs). The procedure was foreseen to run in a 2-step approach as follows:
Download Implementation Process Article 5(3) Nitrosamine
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Pharmaceutical Excipients: A review
www.ijapbc.comActive Pharmaceutical Ingredients make up the dosage forms. Excipients act as protective agents, bulking ... stabilization process alongwith the safety evaluation parameters of the excipients. Keywords: excipient, Interactions, ... Excipients may also contain various impurities which may result in decomposition of the active
5.10. CONTROL OF IMPURITIES IN SUBSTANCES FOR ...
www.pharma.gally.chimpurities that occur in active substances. The thresholds for reporting, identification and qualification contained in the general monographSubstances for pharmaceutical use (2034) apply to all related substances. However, if a monograph does not contain a related substances test based on a quantitative method, any new
Annex 5 WHO good distribution practices for …
www.who.intThe undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or on to a starting material, intermediate or pharmaceutical product during handling, production, sampling, packaging or repackaging, storage or transportation. contract Business agreement for the supply of goods or performance of work at a
Guidelines on the quality, safety, and efficacy of ...
www.who.intnew and provides guidelines on nonclinical evaluation, while Part C, also new, provides guidance on clinical evaluation. The nature and extent of characterization and testing (Part A) required for a product undergoing nonclinical and clinical studies will vary accoding to the nature of the product and its stage of development. The legal status of
Lessons learnt from presence of N-nitrosamine impurities ...
www.ema.europa.euLessons learnt from presence of N-nitrosamine impurities in sartan medicines . Overview and recommendations . Overview . In mid-2018, the European medicines regulatory network. 1. became aware of the presence of . N-nitrosamines in sartan. 2. active pharmaceutical ingredients (APIs) and instituted regulatory action s